GET DAILY SIGNALSWhy Is Recursion Pharmaceuticals (RXRX) Stock Down -3.15% Today?
Key Takeaways
- Recursion Pharmaceuticals RXRX shares fell 3.15% to $3.69 in intraday trading, down from a prior close of $3.81.
- The decline reflects profit-taking after the stock surged roughly 8.1% in the previous session.
- Insider selling and a recently completed $200 million equity offering continue to create a dilution and sentiment overhang.
- Valuation skepticism persists for the loss-making, high-short-interest AI-biotech name even as its pipeline advances.
- Broader caution in biotech and growth stocks amplified the pullback.
- Traders are watching upcoming clinical readouts for REC-4881 and REC-1245, partnership milestones, and the next earnings report.
- For deeper analysis, explore detailed Price Targets, Earnings, and Forecast pages on Tickeron.
- For automated trading ideas, explore Trending AI Robots.
Opening Summary
Recursion Pharmaceuticals, Inc. (RXRX) — a Salt Lake City-based clinical-stage "TechBio" company that uses its Recursion Operating System and artificial intelligence to industrialize drug discovery — saw its shares retreat 3.15% in Tuesday's session, falling to $3.69 from a prior close of $3.81. The move lower came as investors locked in gains following a roughly 8.1% rally in the previous session, with persistent concerns around insider selling, recent financing dilution, and the company's still-loss-making profile tempering the earlier enthusiasm.
Profit-Taking After a Sharp Rally
The most immediate driver of the decline was simple profit-taking. RXRX shares had climbed sharply in the prior session as the market digested a wave of positive news from the company's early-November update, including upbeat clinical data and a new Sanofi partnership milestone. When a heavily shorted, momentum-sensitive stock posts a large single-day gain, short-term traders frequently sell into strength the following session, and Tuesday's action fit that pattern as the stock gave back a portion of its recent advance.
Insider Selling and Dilution Overhang
Adding pressure was a steady drumbeat of insider selling. Director Blake Borgeson disclosed the sale of additional shares in the days following the company's results, part of a broader multi-month pattern in which insiders — including the chief executive and several directors — have trimmed holdings with no corresponding open-market purchases. While much of the activity reflects pre-arranged 10b5-1 trading plans rather than a fresh change in outlook, the optics of continued insider sales tend to weigh on investor sentiment, particularly at a company still years from product revenue.
The overhang is compounded by the company's recently completed $200 million common stock offering, which added to the share count and diluted existing holders. Though the raise extended Recursion's cash runway into 2029 and was positioned as strengthening the balance sheet, equity financings at a clinical-stage company often pressure the share price in the near term.
Valuation Skepticism and Sector Sentiment
Beyond company-specific factors, the pullback reflects persistent valuation skepticism. Recursion remains deeply unprofitable — it reported a net loss of roughly $119 million in the third quarter — with revenue that is still largely driven by collaboration and licensing milestones rather than product sales. The stock also carries a high short interest, estimated at roughly one-third of the float, making it vulnerable to sharp swings in either direction. On days when broader biotech and high-beta growth names trade defensively, RXRX tends to underperform, and Tuesday's session showed that dynamic at work.
Market Context and Trading Activity
The decline unfolded on active trading, consistent with the elevated volume that has accompanied the stock's recent volatility. The move was more pronounced than the broader market's, underscoring that it was driven primarily by stock-specific and sector dynamics rather than a broad index selloff. Technically, the shares remain well off their 52-week high and are trading in a range that has attracted both momentum buyers and short sellers, with the pullback bringing the stock back toward levels seen before its most recent rally.
What Comes Next for RXRX
Looking ahead, RXRX faces several catalysts. The company recently highlighted positive Phase 2 data for REC-4881 in familial adenomatous polyposis and encouraging early single-agent activity for REC-1245 in solid tumors, with further data expected to arrive over the coming quarters. Partnership developments — including Sanofi's recent option of a development candidate and potential milestone payments — could also move the stock. At the same time, risks remain: ongoing cash burn, reliance on milestone-based revenue, insider selling, and the uncertain timeline to any regulatory approval all introduce meaningful uncertainty. Traders will be watching clinical updates, financing activity, and the next quarterly report for direction.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots covering thousands of tickers, including RXRX. These bots vary by strategy, timeframe, performance metrics, and traded symbols, and only the strongest performers under current market conditions are featured. Explore the page to see which AI trading strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
RXRX in upward trend: price rose above 50-day moving average on November 09, 2026
RXRX moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend. In 51 of 55 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on RXRX as a result. In 83 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
The 50-day moving average for RXRX moved above the 200-day moving average on October 12, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +8.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where RXRX advanced for three days, in 208 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Bearish Trend Analysis
The 10-day RSI Indicator for RXRX moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 25 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for RXRX turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 42 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RXRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
RXRX broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for RXRX entered a downward trend on November 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.063) is normal, around the industry mean (3.498). P/E Ratio (-3.520) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (30.030) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. RXRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 74 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RXRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement